- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05676684
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF)
Sodium-glucose Cotransporter 2 Inhibitor, Aldosterone Antagonist, or Both for Heart Failure With Preserved Ejection Fraction: a Two-centre Randomised Three-treatment Three-period Crossover Trial
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Janete Santos, PhD
- Phone Number: (+351) 961239890
- Email: investigaclinica@med.up.pt
Study Contact Backup
- Name: João P. Ferreira, MD, PhD
- Phone Number: (+351) 220426820
- Email: jpferreira@med.up.pt
Study Locations
-
-
-
Porto, Portugal, 4200-319
- Recruiting
- Centro Hospitalar Universitario Sao Joao
-
Contact:
- Centro Hospitalar Universitário São João
- Phone Number: (+351) 225512100
- Email: geral@chsj.min-saude.pt
-
Contact:
- Francisca Saraiva, PhD
- Email: f.saraiva@med.up.pt
-
Principal Investigator:
- Adelino Leite-Moreira, MD, PhD
-
Porto, Portugal, 4434-502
- Recruiting
- Centro Hospitalar Vila Nova de Gaia/Espinho
-
Contact:
- Centro Hospitalar Vila Nova de Gaia/Espinho
- Phone Number: (+351) 227865100
- Email: geral@chvng.min-saude.pt
-
Contact:
- Ana Oliveira, MSc
- Email: crisoliveira@med.up.pt
-
Principal Investigator:
- Ricardo Fontes-Carvalho, MD, PhD
-
Porto, Portugal, 4200-319
- Recruiting
- Faculty of Medicine (FMUP)
-
Contact:
- Francisca Saraiva, PhD
- Phone Number: (+351) 225512100
- Email: f.saraiva@med.up.pt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- HFpEF diagnosis* (irrespective of time from diagnosis)
- Male or female patients, aged ≥50 years
- NYHA Class II-IV
- LVEF ≥45%
- NT-pro BNP ≥220 pg/mL or BNP ≥80 pg/mL if in sinus rhythm (SR)
- NT-pro BNP ≥660 pg/mL or BNP ≥240 pg/mL if in atrial fibrillation (AF)
Echocardiography with at least one of the following criteria:
- LAVI ≥29 ml/m2 (≥34 ml/m2 if AF)
- Lateral E/e' ≥9
- LVMI ≥115 g/m2 If male or ≥95 g/m2 if female
- LV wall thickness ≥12mm
- eGFR ≥30 ml/min/1.73m2 (CKD-EPI formula)
- Blood Potassium ≤5.5 mmol/L
- Not treated with MRAs and/or SGLT2i within the previous month before inclusion and have no history of diabetic ketoacidosis while in treatment with SGLT2 inhibitors
- Stable/chronic ambulatory patients i.e., patients without need for hospitalization within the last 30 days due to heart failure decompensation episodes
If female, she must be a woman of non-childbearing potential. That is, she must be:
- Surgically sterilized (e.g. underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy)
- Clinically diagnosed infertile
- In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause.
A female patient of childbearing potential must have a negative serum pregnancy test at Visit 1 (Day 0) and must agree to consistently and correctly use (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception:
- Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject)
- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
- Intrauterine device
- Intrauterine hormone-releasing system
- Bilateral tubal occlusion
- Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner
Exclusion Criteria:
- Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
- Participation in another clinical study with an investigational product during the last month
- Unwilling or unable to sign the informed consent form
- Surgical procedure, coronary, cerebral or peripheral vascular events or sepsis in the prior 90 days
- Cancer (life-limiting or less than 2 years in remission)
- Any previously confirmed autoimmune disease
- Type 1 Diabetes
- Severe hepatic impairment (Child-Pugh class C)
- Ability to walk is, in the investigator's opinion, clearly limited by joint disease or other locomotor problems or lung diseases rather than by cardiorespiratory fitness
- Previously confirmed cardiac amyloidosis
- Severe valvulopathy according to the echocardiogram report
- Patients with a known hypersensitivity or intolerance to spironolactone or dapagliflozin or any of the excipients of the products.
- Female patients currently pregnant (confirmed by a positive pregnancy test) or intent to become pregnant or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [Dapagliflozin] - [Spironolactone] - [Dapagliflozin + Spironolactone]
Drug will be administered according to sequence: Dapagliflozin [week 1-12] - Spironolactone [week 17-28] - Dapagliflozin + Spironolactone [week 33-44] |
A: Dapagliflozin 10 mg once daily
Other Names:
B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
|
Experimental: [Dapagliflozin] - [Dapagliflozin + Spironolactone] - [Spironolactone]
Drug will be administered according to sequence: Dapagliflozin [week 1-12] - Dapagliflozin + Spironolactone [week 17-28] - Spironolactone [week 33-44] |
A: Dapagliflozin 10 mg once daily
Other Names:
B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
|
Experimental: [Spironolactone] - [Dapagliflozin] - [Dapagliflozin + Spironolactone]
Drug will be administered according to sequence: Spironolactone [week 1-12] - Dapagliflozin [week 17-28] - Dapagliflozin + Spironolactone [week 33-44] |
A: Dapagliflozin 10 mg once daily
Other Names:
B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
|
Experimental: [Spironolactone] - [Dapagliflozin + Spironolactone] - [Dapagliflozin]
Drug will be administered according to sequence: Spironolactone [week 1-12] - Dapagliflozin + Spironolactone [week 17-28] - Dapagliflozin [week 33-44] |
A: Dapagliflozin 10 mg once daily
Other Names:
B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
|
Experimental: [Dapagliflozin + Spironolactone] - [Spironolactone] - [Dapagliflozin]
Drug will be administered according to sequence: Dapagliflozin + Spironolactone [week 1-12] - Spironolactone [week 17-28] - Dapagliflozin [week 33-44] |
A: Dapagliflozin 10 mg once daily
Other Names:
B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
|
Experimental: [Dapagliflozin + Spironolactone] - [Dapagliflozin] - [Spironolactone]
Drug will be administered according to sequence: Dapagliflozin + Spironolactone [week 1-12] - Dapagliflozin [week 17-28] - Spironolactone [week 33-44] |
A: Dapagliflozin 10 mg once daily
Other Names:
B: Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
C: Dapagliflozin 10 mg once daily plus Spironolactone 25 mg once daily (can be adjusted according to potassium and renal function)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood levels of NT-pro BNP (Log transformed)
Time Frame: month 3, month 7, month 11
|
Comparison of NT-pro BNP levels between groups
|
month 3, month 7, month 11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients reaching a 20% or greater reduction in NT-proBNP levels
Time Frame: month 3, month 7, month 11
|
Measured in blood samples
|
month 3, month 7, month 11
|
Circulating levels of PICP, PIIINP and CITP
Time Frame: month 3, month 7, month 11
|
Measured in blood samples the circulating levels of procollagen type I carboxy-terminal propeptide (PICP), N-terminal propeptide of procollagen type III (PIIINP), C-terminal telopeptide of collagen type I (CITP)
|
month 3, month 7, month 11
|
Indexed Left Atrial Volume (LAVi)
Time Frame: month 3, month 7, month 11
|
Transthoracic echocardiogram
|
month 3, month 7, month 11
|
Left Ventricular Ejection Fraction (LVEF)
Time Frame: month 3, month 7, month 11
|
Transthoracic echocardiogram
|
month 3, month 7, month 11
|
Lateral E/e
Time Frame: month 3, month 7, month 11
|
Transthoracic echocardiogram
|
month 3, month 7, month 11
|
Indexed Left Ventricular Mass (LVMi)
Time Frame: month 3, month 7, month 11
|
Transthoracic echocardiogram
|
month 3, month 7, month 11
|
Pulmonary Artery Systolic Pressure (PASP)
Time Frame: month 3, month 7, month 11
|
Transthoracic echocardiogram
|
month 3, month 7, month 11
|
Systolic and Diastolic Blood Pressure (SBP/DBP)
Time Frame: month 3, month 7, month 11
|
Measure in the clinical appointment after 5min of seated rest.
Mean of 3 automatic oscillometric measurements
|
month 3, month 7, month 11
|
Estimated glomerular filtration rate (eGFR)
Time Frame: month 3, month 7, month 11
|
Calculated from the serum creatinine using the 2021 CKD-EPI creatinine-based formula
|
month 3, month 7, month 11
|
Microalbuminuria (log-transformed)
Time Frame: month 3, month 7, month 11
|
Spot urine
|
month 3, month 7, month 11
|
Urinary sodium/natriuresis
Time Frame: month 3, month 7, month 11
|
Spot urine
|
month 3, month 7, month 11
|
Serum potassium (K+)
Time Frame: month 3, month 7, month 11
|
Concentration of potassium in the blood
|
month 3, month 7, month 11
|
Health-related quality of life (HR-QoL)
Time Frame: month 3, month 7, month 11
|
HR-QoL assessed by the Kansas City Cardiomyopathy Questionnaire a 23-item instrument.
All items are measured on a Likert scale with 5-7 response options.
KCCQ scores are scaled from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent
|
month 3, month 7, month 11
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Adelino Leite-Moreira, MD, PhD, Faculty of Medicine (FMUP)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Sodium-Glucose Transporter 2 Inhibitors
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Dapagliflozin
- Spironolactone
Other Study ID Numbers
- SOGALDI-PEF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Preserved Ejection Fraction
-
University Hospital, AkershusNovartisActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionNorway
-
University of SienaEuropean Association of Cardiovascular ImagingActive, not recruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionSpain, Greece, Turkey, Portugal, Australia, Belgium, Italy, Mexico, Netherlands, North Macedonia, Romania, Tunisia
-
Istituti Clinici Scientifici Maugeri SpARecruitingHeart Failure With Preserved Ejection Fraction | Heart Failure With Midrange Ejection FractionItaly
-
Milton S. Hershey Medical CenterWithdrawnHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Board of Trustees of Illinois State UniversityUniversity of Colorado, Denver; Abbott; University of North Carolina, Greensboro and other collaboratorsRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Milton S. Hershey Medical CenterCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection FractionUnited States
-
Zhijun SunEnrolling by invitationHeart Failure | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection FractionChina
-
Corvia MedicalWithdrawnHeart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction
-
Occlutech International ABActive, not recruitingHeart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)United States
-
Yale UniversityRecruitingHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure NYHA Class IVUnited States
Clinical Trials on Dapagliflozin
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
AstraZenecaRecruitingLiver CirrhosisSpain, Denmark, Germany, United States, China, Australia, Belgium, Netherlands, Switzerland, Austria, Taiwan, Canada, Czechia
-
AstraZenecaBristol-Myers SquibbCompletedType 2 Diabetes MellitusUnited Kingdom
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedChronic Kidney DiseaseUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
Hiddo Lambers HeerspinkAstraZenecaUnknownChronic Kidney Diseases | ProteinuriaCanada, Malaysia, Netherlands
-
AstraZenecaCompletedHealthy Subjects in Fasted and Fed StateBrazil